Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy

Leukemia Research

Volumn 36, Issue 6, 2012, Pages

  Matsunaga, T ^a,b   Imataki, O ^b   Torii, E ^b   Kameda, T ^b   Shide, K ^b   Shimoda, H ^b   Kamiunten, A ^b   Sekine, M ^b   Taniguchi, Y ^b   Yamamoto, S ^b   Hidaka, T ^b   Katayose, K ^b   Kubuki, Y ^b   Dobashi, H ^a   Bandoh, S ^a   Ohnishi, H ^a   Fukai, F ^b   Shimoda, K ^c  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN ANTIBODY; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY; PEPTIDE; PROTEIN FNIII14; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL HOMING; CELL PROLIFERATION; CHEMOSENSITIVITY; DRUG CYTOTOXICITY; ENDOSTEAL HYPOXIC ZONE; HUMAN; LETTER; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE MARROW; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASM, RESIDUAL; NEOPLASTIC STEM CELLS; U937 CELLS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863400872     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.028     Document Type: Letter

References (16)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Preisler H.D., Anderson K., Rai K., Cuttner J., Yates J., DuPre E., et al. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 1989, 71:189-194.
3. Sipkins D.A. Rendering the leukemia cell susceptible to attack. N Engl J Med 2009, 361:1307-1309.
4. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
5. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010, 28:275-280.
6. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
7. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 91:1158-1165.
8. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004, 18:1-10.
9. Mudry R.E., Fortney J.E., York T., Hall B.M., Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96:1926-1932.
10. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999, 5:662-668.
11. Matsunaga T., Fukai F., Miura S., Nakane Y., Owaki T., Kodama H., et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008, 22:353-360.
12. Parmar K., Mauch P., Vergilio J.A., Sackstein R., Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104:5431-5436.
13. Takubo K., Goda N., Yamada W., Iriuchishima H., Ikeda E., Kubota Y., et al. Regulation of the HIF-1a level is essential for hematopoietic stem cells. Cell Stem Cell 2010, 7:391-402.
14. Krtolica A., Krucher N.A., Ludlow J.W. Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PPI activities. Oncogene 1998, 17:2295-2304.
15. Wen W., Ding J., Sun W., Wu K., Ning B., Gong W., et al. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res 2010, 70:2010-2019.
16. Chua Y.L., Dufour E., Dassa E.P., Rustin P., Jacobs H.T., Taylor C.T., et al. Stabilization of hypoxia-inducible factor-1α protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. J Biol Chem 2010, 285:31277-31284.